Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05324449 · ClinicalTrials.gov registry record · Phase 4
Epidiolex® for Anxiety in Pediatric Epilepsy
A Phase 4 study of Anxiety and Epilepsy, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05324449 is a Phase 4 study of Anxiety and Epilepsy that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 20 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05324449, a Phase 4 study of Anxiety and Epilepsy, has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.
Interventions
- DRUG Cannabidiol 100 MG/ML
Study Locations (1)
Maryland
- Kennedy Krieger Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-05-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05324449
The ClinicalTrials.gov registry entry for NCT05324449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (95% lower). The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Cannabidiol 100 MG/ML is the first listed.
NCT05324449 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05324449 about?
NCT05324449 is a clinical study titled "Epidiolex® for Anxiety in Pediatric Epilepsy". This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.
What is the current status of trial NCT05324449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2022-04-05. Estimated completion is 2025-05-05.
What conditions does trial NCT05324449 study?
This clinical trial studies the following conditions: Anxiety, Epilepsy.
What interventions are being tested in trial NCT05324449?
The interventions under investigation include: Cannabidiol 100 MG/ML (DRUG).
Who is sponsoring clinical trial NCT05324449?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05324449 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.